The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents

Life Sciences

Volumn 62, Issue 17-18, 1998, Pages 1601-1606

  Lloyd, G K ^a   Menzaghi, F ^a   Bontempi, B ^a   Suto, C ^a   Siegel, R ^a   Akong, M ^a   Stauderman, K ^a   Velicelebi, G ^a   Johnson, E ^a   Harpold, M M ^a   Rao, T S ^a   Sacaan, A I ^a   Chavez Noriega, L E ^a   Washburn, M S ^a   Vernier, J M ^a   Cosford, N D P ^a   McDonald, L A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cognition; Locomotion; Nicotinic acetylcholine receptors; SIB 1508Y; SIB 1553A

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE FUMARATE; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; CYTISINE; DIHYDRO BETA ERYTHROIDINE; DOPAMINE; EPIBATIDINE; MECAMYLAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NORADRENALIN; RECEPTOR SUBTYPE; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; CHOLINERGIC STIMULATION; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HIPPOCAMPUS; NONHUMAN; NORADRENALIN RELEASE; PARKINSON DISEASE; RECEPTOR AFFINITY; XENOPUS;

ANIMALS; HUMANS; NEURONS; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; SUBSTRATE SPECIFICITY;

EID: 0032571222     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00114-3     Document Type: Conference Paper

References (22)

1. 1. J. PATRICK and C.W. LUETJE, Biological Basis for Substance Abuse, Korenman, S.G and Barchas, J.D. (eds), 811-94, Oxford University Press, New York (1993).
2. 2. A.I. SACAAN, J.L. DUNLOP and G.K. LLOYD, J. Pharmacol. Exp. Therap. 274 224-230 (1995).
3. 3. K.J. ELLIOTT, S.B. ELLIS, K.J. BERKHAN, L.E. CHAVEZ-NORIEGA, E.C. JOHNSON, G. VELICELEBI and M.M. HARPOLD, J. Mol Neurosci 7 217-228 (1996).
4. 4. K.J. ELLIOTT, A.I. SACAAN, T.S. RAO, G.K. LLOYD and J. COREY-NAEVE, Soc. Neuroscience Abs. 22 603.16 (1996).
5. 5. M.R. PICCIOTTO, M. ZOLI, C. LENA, A. BLEISS, Y. LALLEMAND, N. LE NOVERE, P. VINCENT, E.M. PICH and J-P. CHANGEUX. Nature 374 65-67 (1995).
6. 6. S. LEONARD, C. ADAMS, C.R. BREESE, L.E. ADLER, P. BICKFORD, W. BYERLEY, H. COON, J.M. GRIFFITH, C. MILLER, M. MYLES-WORSLEY, H.T. NAGAMOTO, Y. ROLLINS, K.E. STEVENS, M. WALDO and R. FREEDMAN, Schizophrenia Bull. 22 431-445 (1996).
7. 7. A. CAMPOS0CARO, F.I. SMILLE, E. EOMINGUES DEL TORO, J.C. ROVIRA, F. VINCENTE-AGULLO, J. CHAPULI, J.M. JUlZ, S. SALA, F. SALA, J.J. BALLESTA and M. CRIADO. J. Neurochem. 68 488-497 (1997).
8. 8. A.I. SACAAN, R.T. REID, E.M. SANTORI, P. ADAMS, L.D. CORREA, L.S. MAHAFFY, L. BLEICHER, N.P.D. COSFORD, K.A. STAUDERMAN, I.A. MCDONALD, T.S. RAO and G.K. LLOYD, J. Pharmacol. Exp. Therap. 280 373-383 (1997).
9. 9. L.E. CHAVEZ-NORIEGA, M.S. WASHBURN, J.H. CRONA, and E.C.. JOHNSON, IBC Conference on NAChR as Pharmaceutical Targets, Washington, D.C. July 25-27 (1997).
10. 10. R.T. REID, A.I. SACAAN, P.B. ADAMS, L.D. CORREA, E.M. SANTORI, I.A. MCDONALD, G.K. LLOYD and T.S. RAO, Abs. Soc. Neuroscience, 23 477.17 (1997).
11. th Int. Conference on in vivo Methods, Tenerife, Abs. 162 (1996).
12. 12. A.I. SACAAN, F. MENZAGHI, J.L. DUNLOP, L.D. CORREA, K.T. WHELAN and G.K. LLOYD, J. Pharmacol. Exp. Therap. 276 509-515 (1996).
13. 13. F. MENZAGHI, K.T. WHELAN, V. B. RISBROUGH, T.S. RAO and G.K. LLOYD, J. Pharmacol. Exp. Therap. 280 384-392 (1997).
14. 14. F. MENZAGHI, A.I. SACAAN, R.T. REID, E. SANTORI, L.D. CORREA, P.B. ADAMS, K.T. WHELAN, V.B. RISBROUGH, T.S. RAO, J. SCHNEIDER and G.K. LLOYD, Abs Soc. Neurosci. Abs. 22 602.11 (1996).
15. 15. G.K. LLOYD, T. S. RAO., A. I., SACAAN., R. T. REID., L.D. CORREA., K. WHELAN., V. B. RISBROUGH and F. MENZAGHI. SIB-1765F, a novel nicotinic agonist:profile in models of extrapyramidal motor dysfunction Soc. Neurosci. Abs. 21 # 11.10 (1995).
16. 16. F. MENZAGHI, K.T. WHELAN, V.B. RISBROUGH, T.S. RAO and G.K. LLOYD, J. Pharmacol. Exp. Therap. 280 393-401 (1997).
17. 17. POPE-COLEMAN, A., G. K. LLOYD and J. SCHNEIDER. Abs. Soc Neurosci. 26, #89.8 (1996).
18. 18. B. BONTEMPI, K.T. WHELAN, V.B. RISBROUGH, M.A. JOPPA, N. KILLE, J.J. BUCCAFUSCO, F. MENZAGHI and G.K. LLOYD, Soc. Neuroscience Abs. 23 477.15 (1997).
19. 19. G.K. LLOYD and J.S. SCHNEIDER, Pharmacologist 39 103 (1997).
20. 20. F. MENZAGHI, A.I. SACAAN, R.T. REID, E. SANTORI, L.D. CORREA, P.B. ADAMS, K. WHELAN, V. RISBROUGH, T.S. RAO, J. SCHNEIDER and G.K. LLOYD, Abs. Soc. Neuroscience. 22 602.11 (1966).
21. 21. M. VAN VELSON, J. TINKER, G.K. LLOYD, F. MENZAGHI and J.S. SCHNEIDER, Abs. Soc. Neuroscience 23 737.3 (1997).
22. 22. T.S. RAO, L.D. CORREA, R.T. REID and G.K. LLOYD, Neuropharmacology 35 393-405 (1996).